



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


## Panobacumab

Cat. No.:	HY-P99214
CAS No.:	885053-97-4
Target:	Bacterial
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	Panobacumab (KBPA101) is a fully human IgM/ $\kappa$ monoclonal antibody generated by immortalizing human B lymphocytes against the LPS O polysaccharide of serotype O11 of <i>P. aeruginosa</i> <sup>[1]</sup> .	
<b>In Vitro</b>	<p>Panobacumab (KBPA101) strongly binds to 18 of 20 clinical O11 isolates, functional avidity of KBPA101 to O11 LPS determined by inhibition ELISA is <math>5.81 \times 10^7 \text{ M}^{-1} \pm 2.8 \times 10^7 \text{ M}^{-1}</math><sup>[1]</sup>.</p> <p>Panobacumab (KBPA101) (0.0001-100 ng/mL; 2 h) specifically mediates complement-dependent opsonophagocytosis of <i>P. aeruginosa</i> serotype O11 with an <math>\text{IC}_{50}</math> of 0.16 ng/mL<sup>[1]</sup>.</p> <p>Panobacumab (KBPA101) (0.1-10 ng/mL) shows direct complement-dependent killing of <i>P. aeruginosa</i> serotype O11 cells in a dose-dependent manner<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>	
<b>In Vivo</b>	<p>Panobacumab (KBPA101) (1-4 mg/kg; i.v.; once) protects mice from systemic infection with <i>P. aeruginosa</i> serotype O11 in a murine burn wound model<sup>[1]</sup>.</p> <p>Panobacumab (KBPA101) (0.005-0.4 mg/kg; i.v.; once) protects mice from local lung infection with <i>P. aeruginosa</i> serotype O11 in an acute lung infection model<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>	
	Animal Model:	Female NMRI mice, murine burn wound model <sup>[1]</sup>
	Dosage:	1, 2, or 4 mg/kg
	Administration:	Intravenous injection, single dose
	Result:	Significantly reduced mortality compared to untreated control animals administered either immediately or 4 h postchallenge.
	Animal Model:	BALB/c mice, acute lung infection model <sup>[1]</sup>
	Dosage:	0.005 to 0.4 mg/kg
	Administration:	Intravenous injection, single dose
	Result:	Led to rapid clearance of <i>P. aeruginosa</i> from the lung, completely cleared systemic <i>P.</i>

---



aeruginosa from the spleen, whereas live bacteria were still present in untreated mice at 48 h postchallenge, showed milder macroscopic lung pathology at 6 and 24 h after infection.

---

## REFERENCES

---

[1]. Horn MP, et al. Preclinical in vitro and in vivo characterization of the fully human monoclonal IgM antibody KBPA101 specific for *Pseudomonas aeruginosa* serotype IATS-O11. *Antimicrob Agents Chemother.* 2010 Jun;54(6):2338-44.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA